Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | CASP7 | P55210 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 4/20 | 0.35 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.35 |
| ▸ | APP | P05067 | 2/20 | 0.34 |
| ▸ | AQP1 | P29972 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL842241 | 0.82 | EGFR (0.41) | KDM1ACYP1A2CYP2D6CYP2C9CASP1 | |
| SCHEMBL843182 | 0.80 | ATM (0.42) | KDM1ACASP1CASP7ATMAPP | |
| SCHEMBL842305 | 0.80 | ATM (0.42) | KDM1ACASP1CASP7ATMAPP | |
| SCHEMBL2747884 | 0.79 | GAA (0.51) | ATMTOP2ATOP2BALDH1A1GLA | |
| SCHEMBL1233564 | 0.79 | GRM5 (0.40) | KDM1ACYP1A2CYP2D6CYP2C9CASP1 | |
| SCHEMBL2743823 | 0.77 | GAA (0.36) | CYP1A2CASP7ATMTOP2ATOP2B | |
| SCHEMBL12744366 | 0.73 | APP (0.55) | CYP1A2CYP2D6CYP2C9CACNA2D1TOP2A | |
| SCHEMBL1456601 | 0.72 | ACHE (0.53) | KDM1ACASP1CASP7ATMAPP | |
| SCHEMBL843109 | 0.72 | KDM4E (0.49) | KDM1ACASP1CASP7APPALDH1A1 | |
| SCHEMBL31197385 | 0.72 | KDM4E (0.49) | KDM1ACASP1CASP7APPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8178677-B2 | Hydroxyalkyl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-8143270-B2 | 2-amino 1H-in-imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| EP-1784180-A4 | 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090023720-A1 | 2-Amino 1H-Imidazo Ring Systems and Methods | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-22 | — | — | US | disclosed |
| EP-1851224-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1784180-A2 | 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006098852-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006029115-A2 | 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | KDM1A 3564/4885CYP1A2 179/4885CYP2D6 278/4885 |
| US-20090023720-A1 | 2-Amino 1H-Imidazo Ring Systems and Methods | IL2, IL2RA, IL4I1 | KDM1A 3713/4885CYP1A2 1349/4885CYP2D6 1504/4885 |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | IFNG, IRF3, IFNAR1 | KDM1A 2958/4885CYP1A2 896/4885CYP2D6 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.